Literature DB >> 2110438

In vitro activities of combinations of aztreonam, ciprofloxacin, and ceftazidime against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.

J A Bosso1, B A Saxon, J M Matsen.   

Abstract

The in vitro activities of two-drug combinations of aztreonam, ciprofloxacin, and ceftazidime were studied in 96 clinical isolates of Pseudomonas aeruginosa and in 20 clinical isolates of Pseudomonas cepacia from cystic fibrosis patients. Some synergy was observed with each combination used against P. aeruginosa, but synergy was rare when the combinations were used against P. cepacia.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2110438      PMCID： PMC171623          DOI： 10.1128/AAC.34.3.487

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  3 in total

1.  In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.

Authors:  J A Bosso; B A Saxon; J M Matsen
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

2.  In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis.

Authors:  S C Aronoff; J D Klinger
Journal:  Antimicrob Agents Chemother       Date:  1984-02       Impact factor: 5.191

3.  Activities of various beta-lactams and aminoglycosides, alone and in combination, against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  R K Scribner; M I Marks; A H Weber; M M Tarpay; D F Welch
Journal:  Antimicrob Agents Chemother       Date:  1982-06       Impact factor: 5.191
  3 in total
  7 in total

1.  Biographical feature: John Matsen, M.D.

Authors:  Karen C Carroll
Journal:  J Clin Microbiol       Date:  2014-06-11       Impact factor: 5.948

2.  Use of the E test to assess synergy of antibiotic combinations against isolates of Burkholderia cepacia-complex from patients with cystic fibrosis.

Authors:  G Manno; E Ugolotti; M L Belli; M L Fenu; L Romano; M Cruciani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-01-25       Impact factor: 3.267

3.  Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents.

Authors:  V Plasencia; N Borrell; M D Maciá; B Moya; J L Pérez; A Oliver
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

4.  Comparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis.

Authors:  Juliet E Foweraker; Christian R Laughton; Derek F Brown; Diana Bilton
Journal:  Antimicrob Agents Chemother       Date:  2009-08-24       Impact factor: 5.191

5.  Routine susceptibility testing of four antibiotic combinations for improvement of laboratory guide to therapy of cystic fibrosis infections caused by Pseudomonas aeruginosa.

Authors:  K Weiss; J R Lapointe
Journal:  Antimicrob Agents Chemother       Date:  1995-11       Impact factor: 5.191

6.  Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.

Authors:  S Bonacorsi; F Fitoussi; S Lhopital; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

Review 7.  Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: Guidelines by the Spanish Society of Chemotherapy.

Authors:  J Mensa; J Barberán; A Soriano; P Llinares; F Marco; R Cantón; G Bou; J González Del Castillo; E Maseda; J R Azanza; J Pasquau; C García-Vidal; J M Reguera; D Sousa; J Gómez; M Montejo; M Borges; A Torres; F Alvarez-Lerma; M Salavert; R Zaragoza; A Oliver
Journal:  Rev Esp Quimioter       Date:  2018-02-23       Impact factor: 1.553
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.